We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
4 own
Current Price
$4.03
$0
(0%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
1,004.44M
52-Week High
10.328
52-Week Low
3.57
Average Volume
1.18M
Dividend Yield
--
P/E Ratio
--
Market Capitalization1,004.44M
52-Week High10.328
52-Week Low3.57
Average Volume1.18M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Globe Newswire
26days ago
Preclinical data demonstrate genetic and epigenetic reprogramming can ameliorate T cell exhaustion and enhance stem-like qualities and potency of T cells in various modalities SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-...
Globe Newswire
1month ago
Five poster presentations to include preclinical data describing new T-cell reprogramming technology being incorporated in LYL119, Lyells next product candidate SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell ...
Globe Newswire
2 months ago
SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinicalstage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced today that a poster describing the first-in-human Phase 1 ...
Ticker Report
6 months ago
Lyell Immunopharma (NASDAQ:LYEL Get Rating) had its price target reduced by The Goldman Sachs Group from $21.00 to $12.00 in a report issued on Tuesday, Stock Target Advisor reports. The Goldman Sachs Group currently has a buy rating on the stock. Separately, Zacks Investment Research ...
Zolmax
6 months ago
Lyell Immunopharma (NASDAQ:LYEL Get Rating) had its price target reduced by The Goldman Sachs Group from $21.00 to $12.00 in a report issued on Tuesday, Stock Target Advisor reports. The Goldman Sachs Group currently has a buy rating on the stock. Separately, Zacks Investment Research upgraded Lyell...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$4.03
$0
(0%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00